| Followers | 55 |
| Posts | 1664 |
| Boards Moderated | 0 |
| Alias Born | 12/11/2012 |
Tuesday, December 09, 2014 2:20:05 PM
REPH $2.75 Long here for bottom bounce and recent clinical developments on this one. This one is a low floater 1.77M float per yahoo and trading close to cash value.
Cash Position
"As of September 30, 2014, Recro Pharma had cash and cash equivalents of $23.9 million"
Market cap :
$21.27M (Yahoo)
Catalyst: Mid 2015
"We ended the third quarter with approximately $24 million of cash and cash equivalents, which we believe is sufficient to fund our operations through the end of 2015, well beyond the expected mid 2015 top-line data readout for the recently initiated Post Op Day 1 Phase II trial with our lead candidate Dex-IN,"
Recro Pharma major shareholder Healthcare Master Fun Broadfin Purchases 241,338 Shares -- Dec 2, 2014 Transaction(REPH)
http://tickerreport.com/banking-finance/364452/recro-pharma-major-shareholder-healthcare-master-fun-broadfin-purchases-241338-shares-reph/
Brean Capital has $26 PT on this one:
Recro Pharma Receives a Buy from Brean Capital
Brean Capital analyst Jonathan Aschoff maintained a Buy rating on Recro Pharma (NASDAQ: REPH) on November 21 and set a price target of $26. The company’s shares closed last Friday at $2.84, close to its 52-week low of $2.50.
http://www.analystratings.com/2014/12/08/recro-pharma-receives-a-buy-from-brean-capital/
Chart:
Cash Position
"As of September 30, 2014, Recro Pharma had cash and cash equivalents of $23.9 million"
Market cap :
$21.27M (Yahoo)
Catalyst: Mid 2015
"We ended the third quarter with approximately $24 million of cash and cash equivalents, which we believe is sufficient to fund our operations through the end of 2015, well beyond the expected mid 2015 top-line data readout for the recently initiated Post Op Day 1 Phase II trial with our lead candidate Dex-IN,"
Recro Pharma major shareholder Healthcare Master Fun Broadfin Purchases 241,338 Shares -- Dec 2, 2014 Transaction(REPH)
http://tickerreport.com/banking-finance/364452/recro-pharma-major-shareholder-healthcare-master-fun-broadfin-purchases-241338-shares-reph/
Brean Capital has $26 PT on this one:
Recro Pharma Receives a Buy from Brean Capital
Brean Capital analyst Jonathan Aschoff maintained a Buy rating on Recro Pharma (NASDAQ: REPH) on November 21 and set a price target of $26. The company’s shares closed last Friday at $2.84, close to its 52-week low of $2.50.
http://www.analystratings.com/2014/12/08/recro-pharma-receives-a-buy-from-brean-capital/
Chart:
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
